Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development

Scribe Therapeutics Inc. (SCTX) has filed to raise drug development investment in an IPO, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, targeting atherosclerotic cardiovascular disease. SCTX's lead candidate, STX-1150, uses proprietary ELXR epigenetic silencing, showing >50% LDL-C reduction in nonhuman primates with first human data expected in H1 2027. The company boasts a top-tier founding team, including Nobel Laureate Jennifer Doudna, and strong backers like Eli Lilly and Andreessen Horowitz, but faces high clinical and regulatory risk. Significant capital needs and uneven collaboration revenue highlight the importance of a well-priced IPO and ongoing investor support for SCTX's pipeline advancement.